Multi-omics analyses reveal significant differences in the gut microbiota and metabolites in children with Kawasaki disease in Northwest China - Scorecard - MDSpire
Advertisement
Multi-omics analyses reveal significant differences in the gut microbiota and metabolites in children with Kawasaki disease in Northwest China
Clinical Scorecard: Comprehensive Multi-Omics Study Identifies Distinct Gut Microbiota and Metabolite Variations in Kawasaki Disease Among Children in Northwest China
At a Glance
Category
Detail
Condition
Kawasaki Disease (KD)
Key Mechanisms
Systemic vasculitis with gut microbiota and metabolomic alterations.
Target Population
Children under 5 years old with Kawasaki Disease.
Care Setting
Pediatric clinical settings in Northwest China.
Key Highlights
Significant reductions in gut microbiota diversity in KD children.
Pathogenic species like Enterococcus avium and Clostridioides difficile are more abundant in KD.
49 metabolic pathways differ between KD children and healthy controls.
Altered fecal and plasma metabolomes in KD children indicate potential biomarkers.
KD is a leading cause of acquired heart disease in children globally.
Guideline-Based Recommendations
Diagnosis
Follow the 2017 statement on Diagnosis, Treatment and Long-Term Follow-Up of Kawasaki Disease.
Management
Consider potential therapeutic targets identified through microbiota and metabolomic studies.
Monitoring & Follow-up
Monitor for coronary artery aneurysms in untreated KD children.
Risks
Untreated KD may lead to coronary artery dilatation, myocardial infarction, and ischemic cardiomyopathy.
Patient & Prescribing Data
Children diagnosed with Kawasaki Disease.
Investigate gut microbiota and metabolomic profiles for potential therapeutic interventions.
Clinical Best Practices
Integrate multi-omics approaches in understanding KD pathogenesis.
Utilize findings on gut microbiota and metabolites for developing diagnostic biomarkers.
Adhere to ethical guidelines in pediatric research.
